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Available online 8 April 2017Adenoid cystic carcinoma (ACC) is an uncommonmalignancy of the salivary glands that is characterized by local
recurrence and distant metastasis due to its resistance to conventional therapy. Platinum-based therapies have
been extensively explored as a treatment for ACC, but they show little effectiveness. Studies have shown that a
specific group of tumor cells, harboring characteristics of cancer stem cells (CSCs), are involved in
chemoresistance of myeloid leukemias, breast, colorectal and pancreatic carcinomas. Therapeutic strategies
that target CSCs improve the survival of patients by decreasing the rates of tumor relapse, and epigenetic
drugs, such as histone deacetylase inhibitors (HDACi), have shown promising results in targeting CSCs. In this
study, we investigated the effect of the HDACi Suberoylanilide hydroxamic acid (Vorinostat), and cisplatin,
alone or in combination, on CSCs and non-CSCs from ACC. We used CSCs as a biological marker for tumor resis-
tance to therapy in patient-derived xenograft (PDX) samples and ACC primary cells. We found that cisplatin re-
duced tumor viability, but enriched the population of CSCs. Systemic administration of Vorinostat reduced the
number of detectable CSCs in vivo and in vitro, and a low dose of Vorinostat decreased tumor cell viability. How-
ever, the combination of Vorinostat and cisplatin was extremely effective in depleting CSCs and reducing tumor
viability in all ACC primary cells by activating cellular senescence. These observations suggest that HDACi and in-
tercalating agents act more efficiently in combination to destroy tumor cells and their stem cells.
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. This is an open access article under1. Introduction
Adenoid cystic carcinoma (ACC) are rare and highly aggressive neo-
plasms of salivary glands and the breast. ACC of the salivary gland rep-
resents approximately 22% of all salivary gland malignancies; these
tumors are slow-growing and have a high potential for local recurrence
(Hitre et al., 2013; Duberge et al., 2012; Hotte et al., 2005). The treat-
ment of choice for ACC is surgical resection followed by postoperative
radiotherapy. While the effectiveness of chemotherapy in treating ACC
has been extensively studied, outcomes remain poor (de Haan et al.,
1992; Licitra et al., 1991; Lagha et al., 2012). Following treatment, 29%
to 40% of patients with ACC experience a disease-free survival of
10 years (Fordice et al., 1999). The majority of deaths from salivary
ACC are due to local recurrence and distant metastasis and are associat-
ed with resistance to conventional therapy. Due to the low incidence ofthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Levels of cancer stem cells in patient-derived xenograft (PDX) and primary cells of ACC. A. PDX tissue samples stainedwith hematoxylin and eosin (left) and identification of histone
acetyl-H3 (Lys9) and ALDH (right) by immunofluorescence following administration of vehicle, cisplatin (CDDP) or Vorinostat. B. Quantification of cells positive for histone acetyl-H3
(Lys9). C. Quantification of cells positive for ALDH. Five fields were quantified using ImageJ 1.50i software (National Institutes of Health, USA); NS (non-significant, p N 0.05), ** (p b
0.01) and *** (p b 0.001). D. Immunofluorescence of the primary cellular culture of ACC stained with anti-Keratin 7 and anti-Keratin 14 antibodies. E. Tumorsphere assays to analyze
the presence of cancer stem cells in ACC primary cells. Cells were grown in ultra-low adhesion for 5 days, the spheres were stained with hematoxylin and eosin following cytospin,
and the total number of spheres were quantified. The assay was performed in triplicate.
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progression,metastasis, and resistance to treatment are underexplored;
as such, this presents a major roadblock for understanding the biology
of ACC and for expanding ACC therapy beyond the limited number of ef-
fective treatments (Liu et al., 2015a).
Chemotherapy is a standard treatment for patients with advanced
disease, including nonresectable, recurrent, or metastatic tumors. Due
to chemoresistance, the majority of patients die within three years
(Papaspyrou et al., 2011). Indeed, cisplatin and other platinum-based
therapies do not present clear benefits to patient's survival rates
(Adelstein et al., 2012). Intrinsic or acquired resistance limits the effica-
cy of the cisplatin, as evidenced by 30% of patients with primary disease,
and N70% of relapsed patients, showing resistance to cisplatin
(Murdoch, 2007). Several mechanisms contribute to cisplatin
chemoresistance, including alterations in molecular signaling underly-
ing drug influx, drug metabolism, apoptosis, cell survival regulators
and DNA repair (Shen et al., 2012; Huang et al., 2014). Recent studies
show that cancer stem cells (CSCs) are involved in tumor development,
chemoresistance and radioresistance of different tumors including head
and neck cancers (Le et al., 2014).
CSCs, a small fraction of the tumor population, are responsible for
tumor initiation and growth. CSCs are quiescent, self-renew, and are in-
herently resistant to chemotherapy and radiotherapy thereby contrib-
uting to treatment failure (Dragu et al., 2015; Pozzi et al., 2015; Vidal
et al., 2014; Qiu et al., 2015). Conventional chemotherapy targets prolif-
erating cancer cells but fails to target dormant or slow cycling cancer
cells. Initially, chemotherapy and radiotherapy destroy the majority of
cancer cells, leading to reduced tumor volume. However, the CSCs that
evade treatment eventually undergo cell division resulting in disease re-
lapse (Liu et al., 2015b). Therapeutic strategies that target CSCs have the
potential to improve overall survival by decreasing the incidence of
tumor relapse. One strategy to reduce CSCs is via global acetylation of
histones (Shukla and Meeran, 2014; Wagner et al., 2016; Guimaraes et
al., 2016).
Vorinostat (Suberoyanilide hydroxamic acid, SAHA) is an efficient
pan-class I and class II Histone Deacetylase inhibitor approved in 2006
for the treatment of lymphoma (Marks, 2007; Park et al., 2016). Recent
studies have demonstrated that Vorinostat has significant anti-tumor
activity for many solid tumors (Khan and La Thangue, 2012; Kumar et
al., 2015). Vorinostat is currently been used as a single agent in phase
II clinical trial for adenoid cystic carcinoma but it is showing poor re-
sponse rate (Chae et al., 2015). However, Vorinostat has been efficiently
used in combination with other chemotherapeutic agents in several
solid tumors (Park et al., 2016; Gumbarewicz et al., 2016; Pan et al.,
2016; Pettke et al., 2016; Yoo et al., 2016; Pili et al., 2017) and as an ef-
ficient sensitizer for salivary gland tumor (Guimaraes et al., 2016).
In this study, we investigated the efficacy of combined therapy with
Vorinostat (an FDA-approved histone deacetylation inhibitor - HDACi)
and cisplatin in reducing CSCs and tumor cells from ACC primary cells.
We used the population of CSCs as a biological marker for tumor resis-
tance to therapy. Surprisingly, cisplatin enhanced the accumulation of
CSCs in ACC patient-derived xenografts (PDX) and primary cell lines.
In contrast, Vorinostat reduced the number of CSCs in PDX samples
and from primary tumor cells 8 h after treatment. However, prolonged
administration of Vorinostat caused an increase in CSCs in ACC primary
cells despite an overall reduction in tumor cell viability. We found thatFig. 2. Effect of Vorinostat on cancer stem cells. A. Representative IC50 values for ACC primary c
adherent cells, the IC:50 was determined using anMTT assay; cells were seeded in 96-well plat
24 h (Mean± SEMof 3.325± 0.8320). For tumorspheres, cells were grown in ultra-low adhesi
24 h (Mean ± SEM of 1.038 ± 0.2478). Following cytospin, cells were stained with hematoxy
counted. Overall, tumorspheres require a significant lower dose of Vorinostat compared to sa
of cancer stem cells in HACC2A and HACC6 was determined using a flow cytometry assay f
treated with the IC:50 concentration of Vorinostat identified in tumorspheres (1 μM for HACC
ALDH+/CD44+ was plotted in the graphs. NS (non-significant, p N 0.05), *p b 0.05, **p b 0.0
were treated with Vorinostat for 0, 8, 24, 48 or 120 h at the tumorsphere IC:50 concentration
significant, p N 0.05), *p b 0.05, ***p b 0.001.the combination of Vorinostat and cisplatin efficiently depleted CSCs
and reduced primary tumor cell viability via cellular senescence. Collec-
tively, our findings suggest that combined therapy using Vorinostat and
cisplatin may be a viable strategy to prevent the development of tumor
resistance in ACC tumor cells.
2. Materials and methods
2.1. Patient-derived xenograft
PDX was generated by South Texas Accelerated Research Therapeu-
tics (START) in collaboration with the Adenoid Cystic Carcinoma Re-
search Foundation. Briefly, mice received 4 cycles of Vorinostat
(100 mg/kg) or 4 cycles of cisplatin (1.5 mg/kg) (n = 3). Each cycle
corresponded to 5 days of Vorinostat or cisplatin administration and
2 days off treatment. Mice were sacrificed after 2 months, and tumors
were collected. Paraffin-embedded tissues were submitted to the Labo-
ratory of Epithelial Biology at the University of Michigan for processing;
an immunofluorescence assaywas used todetect histoneH3acetylation
and ALDH1 expression.
2.2. Immunohistochemistry/immunofluorescence
For immunohistochemical staining, the slides were incubated over-
night with anti-Acetyl- Histone H3 (Cell Signaling, Danvers, MA, USA)
and then for 60min at room temperature (RT) with the anti-rabbit sec-
ondary antibody (Vector Laboratories, Burlingame, CA, USA). The vector
DAB detection systemwas used following incubationwith diaminoben-
zidine tetrahydrochloride (DAB, Sigma-Aldrich Corp., St. Louis, MO,
USA) and staining with Mayer's hematoxylin. Slides from PDX tissues
were incubated overnight with anti-ALDH1 (BD Biosciences, San Jose,
CA, USA) and anti-Acetyl-Histone H3 (Cell Signaling, Danvers, MA,
USA). Slides were then incubated for 60 min at RT with FITC or TRITC-
conjugated secondary antibody and stained with Hoechst 33,342 for vi-
sualization of DNA content.
2.3. Primary cells
Adenoid Cystic Carcinoma cells lines UM-HACC1, UM-HACC2A, and
UM-HACC-6 were initially described by Warner et al. (2013). Cells were
maintained in a 5% CO2 humidified incubator at 37 °C and cultured in
RPMI 1640 (Thermo Scientific, Waltham, MA, USA) supplemented with
10% Fetal Bovine Serum (Thermo Scientific), 1% antibiotic (Invitrogen,
Carlsbad, CA, USA), 1% L-glutamine (Invitrogen), 20 ng/ml epidermal
growth factor (Sigma–Aldrich, St. Louis, MO, USA), 400 ng/ml hydrocorti-
sone (Sigma–Aldrich), and 5 μg/ml insulin (Sigma–Aldrich). Cells were
treated with Vorinostat (SAHA) (Cayman Chemical Company Ann
Arbor, MI, USA) and cisplatin (Sigma–Aldrich, St. Louis, MO, USA).
2.4. IC50 determination
Cell proliferation was determined using the CellTiter 96TM Aqueous
non-radioactive cell proliferation kit (Promega) according to manufac-
turer instructions. Approximately 5000 cells were plated into 96-well
plates in quintuplicate. Cells were treated with control (vehicle),
Vorinostat (0.1, 0.25, 0.5, 1.0, 2.5, 5.0 and 10.0 μM), or cisplatin (2.5,
5.0, 7.5, 10.0, 12.5, 15.0, 17.5 and 20.0 μg/ml) for 24 h. Cells were
incubated with MTS at 37 °C for 4 h, and the results were assessed by
absorbance (Bio-Tek EL- 311, Bio-Tek Instruments) at 490 nm.ells receiving Vorinostat and cultured in monolayer or in suspension (tumorspheres). For
es in quintuplicate and treated with Vorinostat (0.1, 0.25, 0.5, 1.0, 2.5, 5.0 and 10.0 μM) for
on for 5 days, and Vorinostat (0.1, 0.25, 0.5, 1.0, 2.5, 5.0 and 10.0 μM)was administrated for
lin and eosin. The assay was performed in triplicate, and the total number of spheres was
me cellls growing under attchment conditions (monolayer) (*p b 0.05). B. Accumulation
or ALDH and CD44 following treatment with Vorinostat for different times. Cells were
2A and 1.4 μM for HACC6). The assay was performed in triplicate, and the percentage of
1. C. MTT assay to determine the effect of Vorinostat on cell viability. ACC primary cells
. Cells were seeded in quintuplicate, and the assay was performed in triplicate. NS (non-
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The sphere formation assay was performed as previously described
(Almeida et al., 2016). Briefly, cellswere plated on ultra-low attachment
6-well plates (Corning, New York, USA) and allowed to grow for 5 days.
Spheres growing in suspension were collected at day 5 and transferred
to a glass slide by centrifugation (4 °C) at 1500 rpm for 10 min using a
cytospin system. Spheres were stained with hematoxylin and eosin
and mounted in aqueous mounting media (Sigma).
2.6. Immunofluorescence
Cells were placed on glass coverslips in 12-well plates andfixedwith
absolutemethanol at−20 °C for 5min. Cells were blockedwith 0.5% (v/
v) Triton X-100 in PBS and 3% (w/v) bovine serum albumin (BSA) and
incubated with anti-Acetyl-Histone H3 (Lys9) (Cell Signaling, Danvers,
MA, USA), anti-CK7 (BD Biosciences, San Jose, CA, USA), and anti-CK14
(Cell Signaling, Danvers, MA, USA) as indicated. Cells were thenwashed
three times and incubatedwith FITC or TRITC-conjugated secondary an-
tibody for 60 min at RT and then stained with Hoechst 33,342 for visu-
alization of DNA content. Images were taken using a QImaging ExiAqua
monochrome digital camera attached to a Nikon Eclipse 80iMicroscope
(Nikon, Melville, NY) and visualized with QCapturePro software.
2.7. Flow cytometry
ACC cancer stem cell-like cells were identified by aldehyde dehydro-
genase (ALDH) activity combined with CD44-APC expression (BD Bio-
sciences, clone G44-26) using flow cytometry. The Aldefluor kit
(StemCell Technologies, Durham, NC, USA) was used according to the
manufacturer's instructions to identify cells with high ALDH enzymatic
activity. Cells with or without pretreatment, as indicated in individual
experiments, were suspended with activated Aldefluor substrate
(BODIPY amino acetate) or negative control (dimethylamino benzalde-
hyde, a specific ALDH inhibitor) for 45 min at 37 °C. All samples were
analyzed using a FACS Canto IV (BD Biosciences) at the University of
Michigan Flow Cytometry Core.
2.8. β-Galactosidase assay
Tumor cell lines HACC2A and HACC6 were cultured under normal
culture conditions followed by treatment with Vorinostat, cisplatin, or
their combination. An SA-β-Gal detection kit (Cell Signaling, Senescence
β-Galactosidase Staining Kit #9860) was used to detect cells undergo-
ing senescence. In cells treated with Vorinostat and cisplatin, a blue
color was visualized under a microscope (200× total magnification)
for 16 h.
2.9. Statistical analysis
Statistical analysis was performed using GraphPad Prism (GraphPad
Software, San Diego, CA). Statistical analysis of total cell number was
performed using unpaired Student's t-test. The sphere adhesion assay
was assessed by two-way analysis of variance (ANOVA) followed by
the Bonferroni posttest. CSC clonogenic potential was analyzed using
one-way ANOVA followed by Tukey's multiple comparison tests. Aster-
isks denote statistical significance (*p b 0.05; **p b 0.01; ***p b 0.001;
and NS p N 0.05).Fig. 3. Administration of Cisplatin (CDDP) promotes accumulation of cancer stem cells. A. D
determination for adherent cells after 24 h of cisplatin treatment (2.5, 5.0, 7.5, 10.0, 12.5,
quintuplicate. For tumorspheres, cells were grown in ultra-low adhesion for 5 days, and Cispla
± SEM of 7.675 ± 1.373). Following cytospin, cells were stained with hematoxylin and eosin
Flow cytometry assays to determine the accumulation of cancer stem cells. Cells positive
treatment with CDDP at IC:50. NS (non-significant, p N 0.05), *p b 0.05, ***p b 0.001. C. Cell via
seeded in quintuplicate, and the assay was performed in triplicate. NS (non-significant, p N 0.03. Results
3.1. The presence of cancer stem cells in ACC patient-derived xenograft
(PDX) and primary cell culture of ACC
Epigenetic mechanisms control chromatin modifications during de-
velopment and in response to environmental and hormonal stimuli.
Histone acetylation is one of the most frequent epigenetic alterations
that affects chromatin stability. Histone charge modifications influence
the interaction between DNA and histone core proteins by altering nu-
cleosome contacts and exposing binding sites for transcription (Kimura,
2013; Messier et al., 2016). Epigenetic modifications upregulate various
tumorigenic pathways that are associated with poor clinical outcomes
in patients (Jones and Baylin, 2002).
We examined the acetylation status of histone H3 in PDX tumors re-
ceiving cisplatin or Vorinostat and a possible correlation with levels of
Aldehyde dehydrogenases (ALDH), an enzyme highly expressed in
stem cells (Moreb, 2008). PDX tumor sampleswere graciously provided
by South Texas Accelerated Research Therapeutics (START) in collabo-
ration with the Adenoid Cystic Carcinoma Research Foundation.
Cisplatin alone did not alter the acetylation of histone H3 (Fig. 1A
and B, ns p N 0.05). However, compared to vehicle, cisplatin-induced
the accumulation of ALDH1 positive cells (Fig. 1C, **p b 0.01). As expect-
ed, Vorinostat alone caused an abrupt increase in acetylated histone H3
(Fig. 1A and B, ***p b 0.001) but onlymarginally reduced ALDH+ cells in
PDX (Fig. 1A and C, ns p N 0.05). Interestingly, Cisplatin and Vorinostat
presented opposite profiles of histone acetylation and ALDH+ cells ac-
cumulation in PDX models (Fig. 1B and C, ***p b 0.001). These findings
suggest that cisplatin triggers the accumulation of CSCs in ACC, similar
to what we found in mucoepidermoid carcinomas (Guimaraes et al.,
2016). Similarly, recent studies have shown that cisplatin induces the
accumulation of CSCs in HNSCC xenograft mice and contributes to
tumor relapse (Nor et al., 2014; Adams et al., 2013) and the combination
of Cisplatin and Vorinostat may be a strategy to ACC treatment.
Low passage primary human ACC cells have been isolated and suc-
cessfully cultured (Acasigua et al., 2015; Warner et al., 2016). These
cells are positive for cytokeratin 7 and 14, confirming they originate
from the salivary gland (CK7) and epithelial cells (CK14) (Fig. 1D)
(Tsubochi et al., 2000).
A small population of cancer cells with the characteristics of stem
cells can survive, proliferate and form sphere-shaped colonies when
cultured in anchorage-independent conditions (Almeida et al., 2016;
Dontu et al., 2003). We examined whether four primary ACC cells
lines retained a subpopulation of CSCs using the sphere-forming assays
as a method to enrich CSCs. The four ACC cell lines generated approxi-
mately 20 colonies of tumorspheres after 5 days of culture in ultra-
low adhesion conditions (Fig. 1E), suggesting they retain their CSCs.
Therefore, primary ACC cell cultures can serve as an important tool for
identifying strategies that target CSCs.
3.2. Low doses of Vorinostat control the population of CSCs and reduce tu-
mor viability of ACC
HDACi is a drug that induces global chromatin decondensation by
acetylating histones. Histone acetylation often leads to cell cycle arrest,
enhanced tumor susceptibility to conventional cytotoxic treatment, and
selective toxicity in transformed cells (Frank et al., 2010; Duvic and Vu,
2007). Vorinostat targets histone deacetylase classes I and II, inhibiting
tumor cell proliferation and mitosis (Kelly et al., 2005; Sakajiri et al.,etermination of Cisplatin IC:50 in adherent ACC primary cells and tumorspheres. IC:50
15.0, 17.5 and 20.0 μg/ml) (Mean ± SEM of 4.050 ± 0.8057). MTT was performed in
tin (2.5, 5.0, 7.5, 10.0, 12.5, 15.0, 17.5 and 20.0 μg/ml) was administrated for 24 h (Mean
. The assay was performed in triplicate, and the total number of spheres was counted. B.
(%) for ALDH and CD44 were detected in HACC2A and HACC6 after different times of
bility was determined using MTT after different times of CDDP administration. Cells were
5), **p b 0.01, ***p b 0.001.
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rest, differentiation or apoptosis (Richon et al., 2000; Warrener et al.,
2003). We and others have shown that Vorinostat is an efficient sensi-
tizing agent to chemotherapy in several types of cancers, including
mucoepidermoid carcinomas (Guimaraes et al., 2016), glioblastomas
(Barazzuol et al., 2015), and refractory cutaneous T-cell lymphomas
(West and Johnstone, 2014). HDACi also depletes CSCs from squamous
cell carcinoma and mucoepidermoid carcinoma of the oral cavity
(Guimaraes et al., 2016; Giudice et al., 2013). Although the mechanism
involved in HDACi-induced disruption of CSCs is poorly understood, it is
clear that histone acetylation induces quiescent CSCs to differentiate
into more mature tumor cells (Yoshida et al., 1995; Struhl, 1998;
Melcer et al., 2012).
We examined the effects of Vorinostat in ACC tumor cells and their
CSCs. We first determined the half-maximal inhibitory concentration
(IC50) that affects tumor cells growing in monolayer and tumorspheres
(Fig. 2A). Note that the IC50 is one-fold lower for cells in tumorspheres
compared to cells in monolayer. Further, HACC1 was the most sensitive
to Vorinostat when grown in monolayer and ACC52 was the most
sensitive when grown in suspension (spheres) (Fig. 2A).
The primary tumor cells showed differing doubling times. We used
HACC2A and HACC6 cells, which had similar doubling times, for the re-
maining assays. Our strategy was to sensitize ACC to chemotherapy by
targeting CSCs using HDACi. To this end, we used low doses of Vorinostat,
as determined by the IC50 in tumorspheres, to induce histone acetylation
at relevant levels for CSCs. Interestingly, Vorinostat reduced CSCs in
HACC2A cells for up to 48 h, as determined by CD44 expression and
ALDH enzymatic activity (ALDHbright) (Fig. 2B - HACC2A). HACC6 CSCs
were initially resistant to Vorinostat, an effect that was overcome after
5 days of treatment (Fig. 2B - HACC6). Unexpectedly, low doses of
Vorinostat also significantly reduced the viability of tumor cells cultured
in monolayer (Fig. 2C, ***p b 0.001 after 5 days of treatment).
3.3. Cisplatin as a single agent triggers the accumulation of CSCs in adenoid
cystic carcinoma
Conventional anticancer therapeutics, such as cisplatin, rely on pro-
liferating cells to generate DNA adducts and induce cell death (Wozniak
and Blasiak, 2002).We first determined the IC50 of cisplatin in adherent
tumor cells and in suspension as tumorspheres (Fig. 3A) and then ex-
amined the effects of cisplatin on CSCs in HACC2A and HACC6 tumor
cells. Cells were treated with cisplatin for five days using the concentra-
tions obtained from the IC50 for adherent tumor cells, and CSCs were
identified (ALDHbright CD44+) using flow cytometry. Cisplatin-induced
accumulation of CSCs in ACC tumor cells as early as 8 h after treatment
(Fig. 3B). Previous studies have shown that cisplatin causes the accumu-
lation of CSCs in mucoepidermoid carcinomas from the salivary glands
(Guimaraes et al., 2016) and in head and neck squamous carcinomas
(Nor et al., 2014). As expected, cisplatin efficiently reduced tumor via-
bility beginning 8 h after administration in HACC2A and 24 h after ad-
ministration in HACC6 (Fig. 3C, ***p b 0.001 and **p b 0.01). These
findings also suggest that ACC may develop resistance to intercalating
agents by inducing the accumulation of CSCs.
3.4. Combined administration of Vorinostat and cisplatin disrupts CSCs and
sensitizes tumor cells to chemotherapy
We recently showed that head and neck squamous cell carcinomas
resistant to chemotherapy are characterized by increased chromatinFig. 4. Efficacy of combined Vorinostat/Cisplatin (CDDP) treatment to reduce cancer stem cells a
detect ALDH and CD44 in HACC2A and HACC6 cells after different times of treatment with Vori
μg/ml for HACC6). The assay was performed in triplicate, and the percentage of ALDH+/CD4
Accumulation of cancer stem cells after 120 h of treatment with Vorinostat or CDDP alone o
(0 h of treatment) as the control. C. Cell viability was performed using MTT to determine the
with Vorinostat/CDDP for 0, 8, 24, 48 or 120 h. Cells were seeded in quintuplicate, and the as
Cell viability was determined after 120 h of combined Vorinostat/CDDP treatment. Fold regulaticompaction that is driven by histone deacetylation (Almeida et al.,
2014).We also observed that compacted chromatin prevents the influx
of DNA damage repair (DDR) molecules to the nucleus, prohibiting the
activation of apoptosis. However, HDACi reverses this process and sen-
sitizes tumor cells to chemotherapy (Almeida et al., 2014). Furthermore,
we have observed that tumorspheres cannot retain their organization
for N5 h following administration of HDACi, suggesting that mainte-
nance of CSCs is incompatible with chromatin acetylation (Giudice et
al., 2013). In this study, we examined the therapeutic efficacy of com-
bined administration of low doses of Vorinostat (tumorsphere-rele-
vant) with cisplatin. We first assessed whether this combination
would reduce CSCs in HACC2A and HACC6 cells (Fig. 4A). Vorinostat en-
hanced the efficacy of cisplatin, resulting in complete depletion of CSCs
in HACC2A (***p b 0.001) and a 79.73% reduction of CSCs (from a total of
100% of CSC in the untreated samples to a 20.2% of CSC after 5 days of
treatment) (Fig. 4A and B, **p b 0.01). Combined therapy was more
effective than Vorinostat alone in reducing CSCs (Fig. 4B).
We next found that the combination of Vorinostat and cisplatin sig-
nificantly reduced viability in both cell lines after 5 days of treatment
(Fig. 4C, ***p b 0.001). Further analysis revealed that combined therapy
reduced viability by 73.5% of HACC2A and by 77.5%of HACC6 tumor
cells. These findings suggest a superior efficiency of combined
Vorinostat and cisplatin therapy compared to single agent treatment
(Fig. 4D, ***p b 0.001).
Together, these results suggest that targeted disruption of CSCs
using HDACi is an effective strategy to sensitize ACC tumor cells.
3.5. Combined administration of Vorinostat and cisplatin in ACC primary
cells boosts activation of cellular senescence
Cellular senescence causes irreversible cell cycle arrest inwhich cells
remain metabolically active but with a limited lifespan (Kuilman et al.,
2010; Bartkova et al., 2006). Senescence occurs through alterations in
the p53/p21WAF1 and p16INK4A/pRB pathways and changes in chro-
matin organization, resulting in increased cell volume (Deruy et al.,
2014). We have observed that exposure of tumor cells to HDACi causes
senescence-like morphological changes in cells (Newbold et al., 2016).
We examined whether Vorinostat and cisplatin combination therapy
drive ACC tumor cells to senescence. Cellular senescence can be detect-
ed by γ-H2AX foci formation, the accumulation of senescence-associat-
ed β-Galactosidase, and the accumulation of p16ink4. Cisplatin alone
induced the accumulation of γ-H2AX foci due to its DNA intercalating
effects (Fig. 5A, ***p b 0.001). Vorinostat alone did not cause significant
accumulation ofγ-H2AX foci in any of theACC cells (Fig. 5A, nsp N 0.05).
Combined therapy also induced the accumulation of γ-H2AX foci in
both ACC cell lines (Fig. 5A, ***p b 0.001). Using anothermarker of senes-
cence, we observed a modest increase in SA-β-Gal accumulation in re-
sponse to cisplatin but not Vorinostat (Fig. 5B-graphics-CDDP).
Interestingly, combined therapy led to significant accumulation of SA-β-
Gal in both ACC cell lines beyond the levels achieved with cisplatin
alone (Fig. 5B, ***p b 0.001 for both cell lines).We confirmed our observa-
tions using immunohistological detection of p16ink4. Similar to SA-β-Gal,
p16ink4 accumulated in tumor cells in response to combination treatment
(Fig. 5C, ***p b 0.001). Although not significant, there was also a small ac-
cumulation of p16ink4 in cells treatedwith cisplatin alone. Collectively, our
results suggest that Vorinostat sensitizes tumor cells to cisplatin through a
mechanism that combines a reduction in CSCs with activation of cellular
senescence. Dual administration of Vorinostat and cisplatin may consti-
tute a feasible therapeutic strategy to treat ACC patients.nd tumor cells. A. Accumulation of cancer stem cells was determined by flow cytometry to
nostat (1 μM for HACC2A and 1.4 μM for HACC6) and CDDP (3.0 μg/ml for HACC2A and 3.5
4+ was plotted in the graphs. NS (non-significant, p N 0.05), **p b 0.01, ***p b 0.001. B.
r in combination. Fold regulation and percentages were calculated using untreated cells
effect of combined treatment (Vorinostat/CDDP) in ACC cells. Primary cells were treated
say was performed in triplicate. NS (non-significant, p N 0.05), *p b 0.05, ***p b 0.001. D.
on and percentageswere calculated using untreated cells (0 h of treatment) as the control.
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ACC is one of the most common salivary gland cancers, second only
to mucoepidermoid carcinoma. Almost one-quarter of all patients diag-
nosedwithmalignant salivary gland tumors have ACC, which originates
from the intercalated duct of all major and minor salivary glands in the
oral cavity. The histological features of ACC vary from a solid cellular
growth to tubular or cribriform patterns that are comprised of epithelial
and myoepithelial cells. The incidence of ACC is higher during the 5th
and 6th decades of life, and clinical progression is considerably slow.
Such indolent growth is reflected in the high survival rates within the
first 5 years of diagnosis (70–90%), particularly when compared to
other malignancies. However, the long-term prognosis of patients
with ACC is poor, with a survival rate of 35–40% after 15 years and
10% after 20 years. Moreover, the therapies that target ACC are not stan-
dardized (Chae et al., 2015) and are often ineffective in treating ad-
vanced or metastatic disease (Dillon et al., 2016). There have been few
advances in understanding the biology of ACC because disease inci-
dence is low, resulting in a small number of samples available for use
in research. Furthermore, tumor cell lines are difficult to establish due
to the heterogeneous cellular composition of ACC tumors. Recent ad-
vances in patient-derived xenografts (PDX) for ACC resulted in the de-
velopment of primary cultures of ACC tumors derived from PDX mice
(Warner et al., 2016).
Cancer cells use epigeneticmechanisms to control tumor growth, in-
vasion, and resistance to therapy. Novel therapeutic approaches
targeting epigenetic modifications are considered the new frontier in
cancer therapy. In fact, pharmacological modulation of epigenetic alter-
ations is expected to overcome drug resistance that occurs with current
treatments (Kumar et al., 2015). Therapies that sensitize solid tumors
may be particularly beneficial for diseases known to be resistant to stan-
dard treatments. HDACi induces global chromatin acetylation following
cellular differentiation (Newbold et al., 2016); however, the molecular
mechanisms underlying HDACi efficiency as a sensitizing therapy re-
main poorly understood. Sensitizing therapies are especially important
for tumors inwhich the first line of treatment is inefficient, such as ACC.
Recent evidence has shown that CSCs are a subpopulation of tumor cells
characterized by increased resistance to conventional therapies and by a
propensity to perpetuate tumorigenesis (Frank et al., 2010). In this
study, we proposed sensitizing ACC tumor cells to chemotherapy by in-
ducing the acetylation of tumor histoneswith HDACi. Recent reports re-
veal that osteosarcoma becomes enriched with CSCs following cisplatin
treatment. Similarly, ovarian cancer (Wiechert et al., 2016),
mucoepidermoid carcinomas (Guimaraes et al., 2016), and head and
neck squamous carcinoma (Nor et al., 2014) display increased CSCs in
response to chemotherapy. Therefore, accumulation of CSCs is a poten-
tialmechanismunderlying tumor resistance to therapy (Yu et al., 2016).
We showed that ACC tumor cells had an unexpected accumulation of
CSCs following cisplatin administration (Fig. 3B). Interestingly, cisplatin
monotherapy was still effective at reducing non-CSC tumor cells (Fig.
3C). The mechanism of action of cisplatin involves crosslinking DNA to
generate high levels of DNA double-strand breaks (Fig. 5A). Interesting-
ly, cisplatin also induced modest activation of cellular senescence (Fig.
5B). Other platinum-based chemotherapies, such as Oxaliplatin, induce
cellular senescence, an irreversible process that blocks cell division and
results in cell death (Seignez et al., 2014; Zhao et al., 2004). Indeed, ac-
tivation of senescence is a known driver of tumor suppression (Sager,
1991; Rodriguez-Brenes et al., 2015; Reddel, 2000).Fig. 5. Simultaneous administration of Vorinostat and Cisplatin (CDDP) drives ACC primary c
administration of Vorinostat, CDDP or both in combination (left). γ-H2A.X positive cells wer
quantification of 5 fields are plotted in graphs (right); ns (non-significant, p N 0.05) and ***p
Signaling, Senescence β-Galactosidase Staining Kit) after administration of Vorinostat, CDDP
quantified using ImageJ 1.50i. Results are plotted in graphs (right). ***p b 0.001. C. Accumulat
Vorinostat, CDDP or their combination (left). Positive cells in five fields representing each tre
***p b 0.001.We found that administration of Vorinostat to PDXmice resulted in a
modest reduction in ALDH positive cells, suggesting a potential adverse
effect on CSCs (Fig. 1A and C). Our initial hypothesiswas that Vorinostat,
like themajority of HDACi, would induce differentiation of CSCs. Indeed,
Vorinostat-induced differentiation has been reported in primary sarco-
ma cell lines (Hrzenjak et al., 2006) and human tumor cells derived
from the liver (Yamashita et al., 2003), lung (Platta et al., 2007), and
breast (Newbold et al., 2016; Munster et al., 2001; Salvador et al.,
2013). Also, human pluripotent and embryonic stem cells have high
levels of HDAC that result in differentiation (Yang et al., 2014;
Etchegaray et al., 2015; Kretsovali et al., 2012). We found that
Vorinostat alone caused a reduction in CSCs in ACC cells; however,
one of the cell lines showed a rebound in CSCs to pre-treatment levels
after 5 days of Vorinostat (Fig. 2B - HACC2A). These findings suggest
that each ACC tumor may present a different “window of opportunity”
during the administration of Vorinostat. Thereby, a careful analysis on
the efficacy of Vorinostat in reduce the population of CSCs should be
accessed prior to therapy. Nonetheless, Vorinostat alone reduced non-
CSC tumor cells in ACC cells (Fig. 2C). It is important to note that the ef-
fects of Vorinostat on non-CSC cells were achieved using very low levels
the drug, established as the IC50 dose for tumorspheres (Fig. 2A -
tumorspheres). Interestingly, Vorinostat did not activate DNA damage
response or cellular senescence (Fig. 5).
Cisplatin and Vorinostat alone produced exciting results, but their
combination was extremely efficient in disrupting CSCs and non-CSCs.
After 5 days of combined therapy, CSCs were completely depleted in
HACC2A cells, and a 3.9-fold reduction in CSCs occurred in HACC6
cells (Fig. 4A and B). Vorinostat and cisplatin also reduced the viability
of non-CSC cells in ACC cell lines (Fig. 4C and D), as evidenced by a
2.78-fold reduction in viability in HACC2A cells and a 3.45-fold reduc-
tion in viability in HACC6 cells within the first 5 days of treatment
(Fig. 4D).
The benefits of Vorinostat and cisplatin were evident after an initial
rise in CSCs that occurred between 8 and 24 h after treatment (Fig. 4A).
The spike in CSCsmay be due to activation of cellular senescence, a pro-
cess that follows increased replicative stress and the accumulation of
DNA damage foci. Replicative stress can be activated by several mecha-
nisms including oncogene-induced-senescence and the administration
of pharmacological agents capable of perturbing replication
(Courtois-Cox et al., 2006; Wells et al., 2013; Dobbelstein and
Sorensen, 2015). Cell senescence was initially described in 1961 by
Hayflick and Moorhead as an irreversible process triggered by several
events, including cytotoxic drugs (Kuilman et al., 2010; Hayflick and
Moorhead, 1961; Ewald et al., 2010). Activation of senescence results
in the accumulation of DNA double-strand breaks. Within 16 h of cis-
platin and Vorinostat treatment, we observed accumulation of γ-
H2AX foci, especially in tumor cells receiving combined therapy (Fig.
5A). Cells undergoing senescence began to accumulate endogenous ly-
sosomal β-galactosidase and to express p16ink4 after 48 h of treatment
(Fig. 5B and C). It is interesting that Vorinostat alone did not result in in-
creased DNAdouble strand breaks, but it did augment the accumulation
of double strand breaks,β-galactosidase and p16ink4 expression induced
by cisplatin (Fig. 5A).
In summary, the combination of Vorinostat and cisplatin is effective
in depleting CSCs from ACC and in reducing tumor viability. As a poten-
tial mechanism of action, Vorinostat potentiates the ability of cisplatin
to induce DNA double strand breaks and activate cellular senescence.
Although the precise mechanism by which Vorinostat sensitizes cellsells to senescence. A. Immunofluorescence to detect γ-H2A.X staining in ACC cells after
e quantified using ImageJ 1.50i software (National Institutes of Health, USA). Results of
b 0.001. B. Levels of β-galactosidase were detected using the SA-β-Gal detection kit (Cell
or their combination (left). Positive cells in five fields representing each treatment were
ion of p16INK4 protein was detected using immunocytochemistry after administration of
atment were quantified using ImageJ 1.50i (right). Results are plotted in graphs (right).
103L.O. Almeida et al. / Stem Cell Research 21 (2017) 94–105to cisplatin remains unknown, we predict that enhanced chromatin re-
laxation, resulting in a more effective bond between cisplatin and DNA,
leads to increased crosslinking and transcription of senescence-associated genes. In sum, our findings suggest that the combination of
Vorinostat and cisplatin may be a promising therapy for targeting ACC
tumors.
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